Treats inflammatory papules and pustules of rosacea. ANDA 77819, held by Taro Pharmaceuticals. Metronidazole.
As of Nov 21, 2026, ANDA 77819 (Metronidazole), held by Taro Pharmaceuticals, was first approved by FDA on Jul 18, 2006, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Metronidazole gel is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 18, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metronidazole0.75% · gel;topical | Metronidazole | Rx |
| Mar 28, 2012 | Supplement 1Labeling | Approved | None posted |
| Jul 18, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters